Data as of Q4 2025 (Dec 31, 2025)

LUNG

(LUNG)

Financial Statements · SEC EDGAR XBRL

Revenue
$83.8M
+22.0%
Gross Margin
74.0%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Cost of Revenues
Gross Profit
Operating Expenses & Income
Operating Income
Non-Operating Income/Expense
Net Income
EPS (Basic)
EPS (Diluted)
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
$83.8M
$68.7M
$53.7M
$48.4M
$32.7M
$83.8M
$68.7M
$53.7M
$48.4M
$32.7M
$21.8M
$17.9M
$13.8M
$12.8M
$11.5M
$62.0M
$50.8M
$39.9M
$35.6M
$21.2M
-
-$61.9M
-$58.6M
-$47.3M
-$32.3M
-
-$60.8M
-$58.9M
-$48.7M
-$32.2M
-
$-1.60
$-1.59
-
$-3.16
-
$-1.60
$-1.59
-
$-3.16